Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cilastatin, Imipenem
2. Cilastatin, Imipenem Drug Combination
3. Imipenem - Cilastatin
4. Imipenem - Cilastatin Sodium
5. Imipenem Cilastatin
6. Imipenem Cilastatin Sodium
7. Imipenem Cilastatin, Sodium Salt
8. Imipenem-cilastatin
9. Imipenem-cilastatin Sodium
10. Imipenem-cilastatin, Sodium Salt
11. Mk 0787 Mk 0791 Mixture
12. Mk 0787-mk 0791 Mixture
13. Mk 787 Mk 791 Mixture
14. Mk 787-mk 791 Mixture
15. Primaxin
16. Thienam
17. Tienam 500
18. Zienam
1. 85960-17-4
2. Sodium;(z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoate;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid
3. Imipenem + Cilastatin
4. Imipenem-cilastatin Sodium
5. Imipenem-cilastatin Sodium Mixt.
6. Dtxsid60873393
7. Mfcd01744417
8. Cilastatin Sodium Mixture With Imipenem
9. Imipenem Combination With Cilastatin Sodium
10. Mk-0787 / Mk-0791 (1:1)
11. 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)amino)-7-oxo-, (5r-(5-alpha,6-alpha(r*)))-, Mixt. With (r-(r*,s*-(z)))-7-((2-amino-2-carboxyethyl)thio)-2-(((2,2-dimethylcyclopropyl)carbonyl)amino)-2-heptenoic Acid Monosodium Salt
| Molecular Weight | 679.8 g/mol |
|---|---|
| Molecular Formula | C28H42N5NaO9S2 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 17 |
| Exact Mass | 679.23216456 g/mol |
| Monoisotopic Mass | 679.23216456 g/mol |
| Topological Polar Surface Area | 299 Ų |
| Heavy Atom Count | 45 |
| Formal Charge | 0 |
| Complexity | 1020 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Protease Inhibitors
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)
Digital Content 
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Imipenem + Cilastatin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Imipenem + Cilastatin, including repackagers and relabelers. The FDA regulates Imipenem + Cilastatin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Imipenem + Cilastatin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Imipenem + Cilastatin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Imipenem + Cilastatin supplier is an individual or a company that provides Imipenem + Cilastatin active pharmaceutical ingredient (API) or Imipenem + Cilastatin finished formulations upon request. The Imipenem + Cilastatin suppliers may include Imipenem + Cilastatin API manufacturers, exporters, distributors and traders.
click here to find a list of Imipenem + Cilastatin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Imipenem + Cilastatin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Imipenem + Cilastatin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Imipenem + Cilastatin GMP manufacturer or Imipenem + Cilastatin GMP API supplier for your needs.
A Imipenem + Cilastatin CoA (Certificate of Analysis) is a formal document that attests to Imipenem + Cilastatin's compliance with Imipenem + Cilastatin specifications and serves as a tool for batch-level quality control.
Imipenem + Cilastatin CoA mostly includes findings from lab analyses of a specific batch. For each Imipenem + Cilastatin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Imipenem + Cilastatin may be tested according to a variety of international standards, such as European Pharmacopoeia (Imipenem + Cilastatin EP), Imipenem + Cilastatin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Imipenem + Cilastatin USP).
LOOKING FOR A SUPPLIER?
